Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Hindu
The Hindu
National
PTI

Serum Institute of India to launch vaccine to prevent cervical cancer

Serum Institute of India CEO Adar Poonawalla on July 12 said the company plans to launch its indigenously-developed vaccine to prevent cervical cancer in women later this year.

The Drugs Controller General of India (DCGI) on July 12 granted market authorisation to Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer.

In response to the approval by the drug regulator, Mr. Poonawalla in a tweet said, “For the first time, there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the #DCGI @MoHFW_INDIA  for granting approval today.” The approval by the drug regulator of SII’s anti-cancer vaccine follows recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) of COVID-19 vaccine on June 15, 2021.

The company had applied to the DCGI seeking market authorisation of the qHPV after the phase 2/3 clinical trial was completed with support of the Department of Biotechnology.

Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.